2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Shubham Pant, MD, an associate professor in the departments of Investigational Cancer Therapeutics and Gastrointestinal Medical Oncology, and associate director in the Department of Sheihk Ahmed Center for Early Phase Drug Development of Pancreatic Cancer Research, in the Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, to discuss the landscape of targeted therapy in pancreatic cancer.
In our exclusive interview, Pant discussed the current role for germline and somatic testing in pancreatic cancer, examined the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shared his hope for the future of drug development in the field.